Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Neurosurg Pediatr ; 3(5): 386-91, 2009 May.
Artículo en Inglés | MEDLINE | ID: mdl-19409017

RESUMEN

Intracranial osteolipomas and chondromas are rare benign tumors. Forty-five chondromas, mostly supratentorial, have been reported in the literature since 1981, with origins most commonly in the sellar regions. Twenty-one osteolipomas have been described to date, usually located near the tuber cinereum or the corpus callosum. The authors present a case of an osteochondrolipoma arising from the tentorium diagnosed in a pediatric patient at the age of 9 years. The case and treatment are discussed, and a review of the literature is provided.


Asunto(s)
Neoplasias Infratentoriales/diagnóstico , Lipoma/diagnóstico , Osificación Heterotópica/patología , Osteocondroma/diagnóstico , Tuber Cinereum/patología , Niño , Humanos , Neoplasias Infratentoriales/patología , Neoplasias Infratentoriales/cirugía , Lipoma/patología , Lipoma/cirugía , Imagen por Resonancia Magnética , Masculino , Osificación Heterotópica/fisiopatología , Osificación Heterotópica/cirugía , Osteocondroma/patología , Osteocondroma/cirugía , Tuber Cinereum/fisiopatología , Tuber Cinereum/cirugía
2.
Am J Infect Control ; 36(1): 54-8, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18241737

RESUMEN

Pediatric oncologists from Germany systematically reviewed the literature, considering the use of urokinase in pediatric oncology patients published since 1998 and came to the following conclusions. The use of urokinase to prevent central venous access device (CVAD)-related infections in pediatric cancer patients represents an evidence-based approach, at least in external, tunneled catheters (eg, Hickman, Broviac). The effectiveness of urokinase prophylaxis in decreasing infections and thrombotic events is probably related not only to the concentration and timing of the urokinase intervention but also to the type of CVAD, and perhaps to the intensity of the concomitant chemotherapy program. Urokinase can safely and effectively be used on CVADs with malfunctioning or intraluminal occlusion in a dose of 5000 IU/mL or as salvage 3-hour infusion with 1000 IU/kg/hour. Hitherto, adjuvant treatment with urokinase in the management of CVADs with intraluminal infection still relies on case reports and small case series. In this field, a randomized controlled study is necessary.


Asunto(s)
Coagulación Sanguínea/efectos de los fármacos , Cateterismo Venoso Central/métodos , Quimioprevención/estadística & datos numéricos , Infección Hospitalaria/prevención & control , Neoplasias/complicaciones , Activador de Plasminógeno de Tipo Uroquinasa/farmacología , Catéteres de Permanencia/microbiología , Quimioprevención/métodos , Niño , Alemania , Humanos , Neoplasias/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...